Title:
５−ＨＴ２Ｃ受容体アゴニストおよび組成物、ならびに使用方法
Document Type and Number:
Japanese Patent JP6789578
Kind Code:
B2
Abstract:
Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
Inventors:
Lehman, Yog
Feichtinger, Conrad
Ren, Albert S.
Semple, Graham
Feichtinger, Conrad
Ren, Albert S.
Semple, Graham
Application Number:
JP2018504658A
Publication Date:
November 25, 2020
Filing Date:
July 28, 2016
Export Citation:
Assignee:
Arena Pharmaceuticals, Incorporated
International Classes:
C07D223/16; A61K31/55; A61P3/04; A61P3/10; A61P25/08; A61P25/30; A61P25/32; A61P43/00; C07D223/32; C07D491/06
Domestic Patent References:
| JP2005529894A | ||||
| JP2007516941A | ||||
| JP4235167A |
Foreign References:
| WO2013133325A1 | ||||
| WO2014041131A1 | ||||
| WO2011071136A1 |
Other References:
CLARK,Robin D.,JOURNAL OF MEDICINAL CHEMISTRY,1990年,33,633-641
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Natsuki Morishita